CN111961722A - miR-887在乳腺癌诊断和治疗中的用途 - Google Patents
miR-887在乳腺癌诊断和治疗中的用途 Download PDFInfo
- Publication number
- CN111961722A CN111961722A CN202010680480.6A CN202010680480A CN111961722A CN 111961722 A CN111961722 A CN 111961722A CN 202010680480 A CN202010680480 A CN 202010680480A CN 111961722 A CN111961722 A CN 111961722A
- Authority
- CN
- China
- Prior art keywords
- mir
- breast cancer
- pharmaceutical composition
- expression
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091092836 miR-887 stem-loop Proteins 0.000 title claims abstract description 78
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 55
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 55
- 238000003745 diagnosis Methods 0.000 title description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 230000009545 invasion Effects 0.000 claims abstract description 10
- 230000005012 migration Effects 0.000 claims abstract description 9
- 238000013508 migration Methods 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 9
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 238000001353 Chip-sequencing Methods 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000009400 cancer invasion Effects 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002679 microRNA Substances 0.000 description 10
- 108700011259 MicroRNAs Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000007806 cell migration and invasion assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
本发明提供了检测miR‑887表达的试剂在制备评估乳腺癌风险的产品中的应用,所述miR‑887的核苷酸序列如SEQ ID NO.1所示。进一步,本发明还公开了miR‑887在制备治疗乳腺癌的药物组合物中的应用。本发明首次发现了miR‑887在乳腺癌细胞中表达下调,同时还公开了miR‑887在乳腺癌细胞的增殖、迁移和侵袭中起着重要的作用,提示miR‑887可应用于乳腺癌的治疗。
Description
技术领域
本发明涉及生物医药研究领域,特别是涉及miR-887在乳腺癌诊断和治疗中的用途。
背景技术
乳腺癌(breast cancer)是女性最普遍的恶性肿瘤之一,通常发生在乳腺上皮组织。据资料统计,乳腺癌的发病率占全身各种恶性肿瘤的7-10%。全球每年有135万新增加的乳腺癌,其中有42万死亡,每年递增是2%。中国每年有4万多妇女死于本病,虽然不是乳腺癌高发国家,但是其增长速度远远高于其他国家。它的发病影响因素较多,遗传易感性和基因与环境相互作用均与其发生、进展和转移密切相关。虽然通过之前的研究已经发现了多种致癌基因和抑癌基因,使乳腺癌的诊断率有所提高,治疗效果有所改善,但并不能完全解决问题。因此需要对肿瘤发生的分子机制深入了解,为乳腺癌患者的治疗提供新的有效的治疗方法。在没有完全找到乳腺癌的发病原因之前,乳腺癌的早诊断、早治疗,是降低乳腺癌死亡率的关键。
microRNA是一种不编码蛋白质的,约21-25nt大小的单链小分子RNA。通过特异性的结合靶基因来调控其表达。在过去的几十年,大量的microRNA被发现并认为在细胞的发生、分化、增殖和凋亡起着重要的作用。据报道,miRNAs调控人类60%编码蛋白基因的表达,通过结合其目标基因mRNA的3’非翻译区而导致mRNA的降解或者翻译抑制。除了沉默作用外,某些miRNAs还被证实能激活基因的表达。在不同的肿瘤类型中,microRNA呈现两种不一样的角色:抑癌基因和癌基因。主要的作用机制包括:miRNA位点的缺失、扩增、突变,表观遗传水平改变,转录调控因子的异常表达等。
由于乳腺癌给人类健康带来的巨大危害,研究者们正通过各种途径寻找有效的治疗乳腺癌的方法。分子标志物正在被尝试应用到乳腺癌的诊断和治疗当中。最近的研究表明microRNA(miRNA)在肿瘤的发生发展中发挥着重要作用,寻找与乳腺癌发生发展相关的miRNA对乳腺癌的机制研究以及临床上的诊断和治疗具有重要的意义。
发明内容
鉴于以上所述现有技术的缺点,本发明提供了一种用于评估乳腺癌风险和/或治疗乳腺癌的标记物-miR-887及其应用,并为乳腺癌的治疗提供了新的方法和思路。
为实现上述目的,本发明采用如下技术方案:
本发明的第一方面,提供了检测miR-887表达的试剂在制备评估乳腺癌风险的产品中的应用,所述miR-887的核苷酸序列如SEQ ID NO.1所示。
在一种实施方式中,所述产品用于诊断受试者是否患有乳腺癌风险,通过测量来自所述受试者的测试样品中的miR-887的水平来诊断受试者是否患有乳腺癌风险,其中与对照样品中miR-887的水平相比,测试样品中miR-887的水平下调,指示着受试者患有乳腺癌的风险。
在一些实施方式中,所述试剂包括通过使用qRT-PCR、印记杂交、原位杂交、阵列杂交、基因芯片或新一代测序来检测miR-887或其同源物的水平的试剂。
在一优选实施方式中,所述试剂包括特异性针对miR-887的探针或引物。
本发明的第二方面,提供了miR-887在制备治疗乳腺癌的药物组合物中的应用,所述miR-887的核苷酸序列如SEQ ID NO.1所示。
在一些实施方式中,所述应用包括制备抑制乳腺癌细胞迁移、侵袭和增殖的药物组合物。
在一些实施方式中,所述药物组合物包括促进miR-887表达或增强miR-887功能的试剂。
在一些实施方式中,所述试剂包括miR-887的模拟物、miR-887的激动剂或过表达miR-887的载体。
本发明的第三方面,提供了一种治疗乳腺癌癌/乳腺癌侵袭/乳腺癌转移的药物组合物,所述药物组合物以miR-887为活性成分,其中,所述miR-887的核苷酸序列如SEQ IDNo.1所示。
在一种实施方式中,所述药物组合物含有与载体结合的miR-887和/或药物可接受的辅料。
优选地,所述载体包括病毒载体、脂质体或壳聚糖。
本发明将miR-887作为作用对象,对药物进行筛选,以找到可以促进miR-887表达的激动剂作为乳腺癌治疗备选药物。如本发明所述的miR-887模拟物即是以人miR-887为作用对象筛选获得的,可用作具有抑制乳腺癌细胞增殖、侵袭、迁移作用的药物。
基于上述技术方案,本发明具有以下有益效果:
本发明通过过表达miR-887后可有效地抑制乳腺癌细胞的增殖、迁移、侵袭进程。本发明提供的miR-887核苷酸或模拟物能够特异性抑制乳腺癌细胞的增殖速率、迁移、侵袭,从而治疗乳腺癌,为乳腺癌治疗开辟新的方向。
附图说明
图1 miR-887在乳腺癌细胞中的表达;
图2 miR-887转染模拟物后,Q-PCR检测miR-887的表达量;
图3 miR-887转染模拟物后检测细胞增殖;
图4 miR-887抑制乳腺癌细胞迁移和侵袭结果图。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
在本发明中,术语“miR-887”是指包含SEQ ID No.1所示序列或其同源序列的微小RNA。本领域中已知各种来源的miR-887,例如,人、鼠、兔等,这些同源序列均包含在本发明的术语miR-887中。本发明的术语中还包含上述天然存在的miR-887序列经取代、缺失或添加一个或几个核苷酸,或经过生物学化学修饰后仍具有miR-887生物活性的衍生RNA。
本发明中,人工合成的以及可以通过购买市售商品方式获得的具有miR-887生物学活性的miR-887模拟物也属于本发明的保护范围。
此外,本发明所述的miR-887也可以为前体形式,miR-887前体是指在被施用对象的细胞内或体内可以被加工成为miR-887的前体。获得天然存在的miR-887前体的方法为本领域技术人员所公知。
本领域技术人员公知,miR-887的初始转录产物经过一系列的加工后,形成成熟的miR-887。miR-887前体只有在加工成成熟的miR-887后才具有相应的生物学功能。
本发明的统计学分析:
所有数据采用均数±标准差(mean±SD)表示。两组间比较采用双侧Student's t检验。所有结果均采用GraphPad Software软件进行绘图,以P<0.05为检验水准,当P<0.05为差异有统计学意义。
实施例1 QPCR检测miR-887在乳腺癌细胞中的表达
发明人检测MCF10A(对照细胞)、MCF-7、MDA-MB-231细胞中miR-887的表达水平。
1.miRNA提取
使用Tiangen的miRNA提取试剂盒,每200μl细胞中加入等体积裂解液,振荡器振荡混匀30秒。室温放置5min后,12,000rpm离心10min,取上清,加入200μl氯仿,剧烈振荡15秒,室温放置5min后,12,000rpm离心15min,样品会分成三层:黄色的有机相,中间层和无色的水相,RNA主要在水相中,把水相转移到新管中,缓慢加入转移液体积1/3体积的无水乙醇混匀,一起转入吸附柱,室温放置2min,12,000rpm离心30秒,保留流出液。缓慢加入流出液体积2/3体积的无水乙醇,混匀,一起转入吸附柱,室温放置2min后12,000rpm离心30秒,离心后保留吸附柱。向吸附柱中加入500μl去蛋白液,室温12,000rpm离心30sec,弃废液。500μl漂洗液,室温12,000rpm离心30秒。将吸附柱放入2ml收集管中,室温12,000rpm离心1min,去除残余液体。再将吸附柱转入一个新的1.5ml离心管中,加15-30μl无RNA酶的水,室温12,000rpm离心2min。
2.逆转录
将10pg-1μg的RNA模板与2μl 10倍缓冲液、2μl dATP(10mM)、0.5μl引物、0.5μl核糖核酸酶抑制剂和无核糖核酸酶水混合,体积最后为20μl,37℃孵育1h。然后反应管中加入1μl 0.5μg/μl特异性RT引物,70℃孵育5min后立刻冰上孵育至少2min,打断RNA和引物的二级结构。最后,将上述20μl反应混合物与4μl 5倍缓冲液、1μl dNTP(10mM),0.5μl M-MLV逆转录酶,0.5μl核糖核酸酶抑制剂,10μl polyA反应混合液和4μl无核糖核酸酶水混合,42℃孵育1h。
3.Q-PCR检测
采用25μl反应体系,每个样本设置3个平行管,所有扩增反应均重复三次以上以保证结果的可靠性。配制以下反应体系:SYBR Green聚合酶链式反应体系12.5μl,正向引物(5μM/l)1μl,反向引物(5μM/l)1μl,模板cDNA2μl,无酶水8.5μl。各项操作均于冰上进行。扩增程序为:95℃10min,(95℃20s,60℃55s)40个循环。以SYBR Green作为荧光标记物,在荧光实时定量PCR仪上进行PCR反应。通过融解曲线分析和电泳确定目的条带,2-ΔΔCT法进行相对定量。
4.结果
结果如图1所示,与对照细胞MCF10A相比,miR-887-5p在人乳腺癌细胞系中MCF-7、MDA-MB-231细胞中低表达,*P<0.05。
实施例2 miR-887基因对乳腺癌细胞增殖的影响
实验中所用的mimics NC(阴性对照)和miR-887mimics均由上海吉玛公司合成。
用转染试剂LipofectamineTM 3000将miR-887mimics(miR-887模拟物)转染乳腺癌MDA-MB-231细胞中,具体步骤如下:
1)转染前24h,在装有培养基的6孔板中接种3.0×105个细胞,转染时细胞融合度达到50%;
2)配制转染物:9μ1miR-887mimics及NC中加入125μl无血清无抗生素的RMPI 1640培养基,每孔加入5μl的LipofectamineTM 3000试剂,充分吹打混匀,后静置5min;
3)用吸管吸去6孔板中的培养液,然后在每孔中加入提前配好的800μl含10%胎牛血清的培养液和转染物;
4)轻轻晃动培养板,使试剂充分混合,置于培养箱中继续培养,6h后,更换新鲜的培养液。
用Q-PCR检测其表达量,具体步骤参照实施例1所述。结果如图2表明,miR-887mimics转染MDA-MB-231后细胞中miR-887表达量显著性上升(*P<0.05),证明mimics能够模拟miR-887的表达。
进一步,miR-887mimics转染MDA-MB-231细胞24、36、48、72和96h后,体外用CCK-8试剂盒检测细胞增殖,具体步骤如下:
转染后的MDA-MB-231细胞培养72h,用0.25%胰酶消化进行细胞计数,将细胞接种于96孔板中,浓度为1×104/ml,每孔加100μl;避光条件下,96孔板中每孔加入10μl的CCK8试剂,晃动培养板3min,然后将培养板放入培养箱中继续培养,2h后取出,在酶标仪450nm波长处测定OD值。
结果如图3,过表达miR-887后,相比对照,细胞增殖明显受到抑制(*P<0.05)。可见,miR-887能够显著性抑制乳腺癌细胞的增殖。
实施例3细胞迁移及侵袭实验
1、侵袭实验
Matrigel用PBS进行20倍稀释,以50μl/孔的体积铺在Transwell小室的聚碳酸酯膜上。37℃预置2h聚合成凝胶备用。每组设3个复孔,上室每孔加入200μl细胞悬液,约1×l05个;在下室加入500μl含FBS的RMPI 1640培养基,置于37℃、5%CO2条件下培养24h后用70%甲醇固定,0.4%结晶紫染色,封片后随机选取4个视野(x100)计穿膜细胞数,取平均值。
2、迁移实验
过程与Transwell侵袭实验基本一致,但不需要铺Matrigel胶及培养板置于37℃、5%CO2条件下培养8h。
3、结果
结果如图4所示,与对照组相比,实验组的迁移及侵袭能力均有明显下降(*P<0.05),结果说明miR-887水平的升高能够抑制乳腺癌的迁移及侵袭,提示miR-887可作为靶标应用于乳腺癌转移的治疗。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
序列表
<110> 北京大学深圳医院
<120> miR-887在乳腺癌诊断和治疗中的用途
<130> P200232
<141> 2020-07-15
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> miR-887
<400> 1
cttgggagcc ctgttagact c 21
Claims (10)
1.检测miR-887表达的试剂在制备评估乳腺癌风险的产品中的应用,所述miR-887的核苷酸序列如SEQ ID NO.1所示。
2.根据权利要求1所述的应用,其特征在于,所述试剂包括通过使用qRT-PCR、印记杂交、原位杂交、阵列杂交、基因芯片或新一代测序来检测miR-887或其同源物的水平的试剂。
3.根据权利要求1所述的应用,其特征在于,所述试剂包括特异性针对miR-887的探针或引物。
4.miR-887在制备治疗乳腺癌的药物组合物中的应用,所述miR-887的核苷酸序列如SEQ ID NO.1所示。
5.根据权利要求4所述的应用,其特征在于,所述应用包括制备抑制乳腺癌细胞迁移、侵袭和增殖的药物组合物。
6.根据权利要求5所述的应用,其特征在于,所述药物组合物包括促进miR-887表达或增强miR-887功能的试剂。
7.根据权利要求6所述的应用,其特征在于,所述试剂包括miR-887的模拟物、miR-887的激动剂或过表达miR-887的载体。
8.一种治疗乳腺癌/乳腺癌侵袭/乳腺癌转移的药物组合物,其特征在于,所述药物组合物以miR-887为活性成分,其中,所述miR-887的核苷酸序列如SEQ ID No.1所示。
9.根据权利要求8所述的药物组合物,其特征在于,所述药物组合物含有与载体结合的miR-887和/或药物可接受的辅料。
10.根据权利要求9所述的药物组合物,其特征在于,所述载体包括病毒载体、脂质体或壳聚糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010680480.6A CN111961722A (zh) | 2020-07-15 | 2020-07-15 | miR-887在乳腺癌诊断和治疗中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010680480.6A CN111961722A (zh) | 2020-07-15 | 2020-07-15 | miR-887在乳腺癌诊断和治疗中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111961722A true CN111961722A (zh) | 2020-11-20 |
Family
ID=73360843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010680480.6A Pending CN111961722A (zh) | 2020-07-15 | 2020-07-15 | miR-887在乳腺癌诊断和治疗中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111961722A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103882118A (zh) * | 2014-02-13 | 2014-06-25 | 绍兴市人民医院 | 用于检测前列腺癌的miRNAs |
CN106488986A (zh) * | 2014-06-13 | 2017-03-08 | 东丽株式会社 | 乳癌的检测试剂盒或装置以及检测方法 |
-
2020
- 2020-07-15 CN CN202010680480.6A patent/CN111961722A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103882118A (zh) * | 2014-02-13 | 2014-06-25 | 绍兴市人民医院 | 用于检测前列腺癌的miRNAs |
CN106488986A (zh) * | 2014-06-13 | 2017-03-08 | 东丽株式会社 | 乳癌的检测试剂盒或装置以及检测方法 |
Non-Patent Citations (2)
Title |
---|
KAREN C. B. SOUZA等: "Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping", 《JOURNAL OF ONCOLOGY》 * |
KRISTEN FITE等: "Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 Prevents Vimentin-triggered, Phospholipase D (PLD)-mediated Cancer Cell Invasion", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111778338B (zh) | 一种环状rna生物标志物的应用 | |
Gong et al. | LncRNA HAND2‐AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74 | |
CN111118013B (zh) | 白血病生物标志物linc02033及其应用 | |
CN113201591B (zh) | 一种长链非编码rna及其抑制剂在预防、治疗乳腺癌中的应用 | |
CN106929577B (zh) | 一种与肺腺癌相关的lncRNA生物标志物 | |
CN108085389B (zh) | 一种与乳腺癌相关的lncRNA及其应用 | |
CN114807372A (zh) | 人HHIPL2 mRNA在食管鳞状细胞癌靶向治疗和预后评估中的应用及试剂盒 | |
CN108251528B (zh) | Linc01814在胃癌诊治中的应用 | |
CN111172290B (zh) | 肝细胞癌诊断和治疗的miRNA | |
CN110923324A (zh) | 一种乳腺癌miRNA标记物及其应用 | |
CN108192977B (zh) | 一种与胃癌发生发展相关的分子标志物 | |
CN111961722A (zh) | miR-887在乳腺癌诊断和治疗中的用途 | |
CN112359115B (zh) | 与肿瘤细胞顺铂耐药性相关的miR-517a-3p及其应用 | |
CN108660211B (zh) | 一种与肝细胞癌相关的生物标志物linc01549及其应用 | |
CN111973744B (zh) | Plce1-as2在乳腺癌中的应用 | |
CN111349704B (zh) | 肝癌的诊断产品和治疗组合物 | |
CN112410430B (zh) | 一种与肿瘤细胞对顺铂耐药性相关的标志物及其应用 | |
CN112941183B (zh) | 非编码基因miR-187-5p在原发性肝癌诊疗中的应用 | |
CN114958856B (zh) | 长链非编码rna cyp1b1-as1作为乳腺癌生物标志物和治疗靶点的应用 | |
CN110946872B (zh) | miR-4491在制备治疗乳腺癌的药物中的应用 | |
CN116790753B (zh) | 联合靶向USP21与G3BP1 mRNA在治疗人食管鳞状细胞癌中的应用 | |
CN114107495B (zh) | Duxap8在子宫内膜癌诊断、治疗和预防中的应用 | |
CN112961918B (zh) | lncRNA在口腔癌诊断和治疗中的应用 | |
CN112980957B (zh) | 抑制非小细胞肺癌转移的靶标hsa_circ_0001326及其应用 | |
CN113789340B (zh) | 环状RNA hsa_circ_0001741的表达载体、重组工程菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |